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a b s t r a c t
Objective: To assess if the initial results of viscosupplementation are improved by the 
addition of corticosteroid. Design: We evaluated 104 patients receiving usual care for knee 
osteoarthritis at the Universidade de São Paulo Medical Center. Patients were randomized 
to receive either a single intra-articular injection of 6 mL of Hylan GF-20 (Group 1) or a 
single intra-articular injection of 6 mL of Hylan GF-20 plus 1 mL (20 mg) of Triamcinolone 
Hexacetonide (Group 2). VAS, WOMAC and Lequesne questionnaires were applied at 
weeks zero (prior the injection), and after one, four, and 12 weeks. Results: The baseline 
measurements of the two groups with 52 patients each were not statistically different. 
At week one, WOMAC and VAS showed significantly better results for Group 2 compared 
to Group 1 (p < 0,05). At week four the scores did not show a statistically significant 
differences. The groups showed similar results at week 12. Conclusion: The addition of 
Triamcinolone Hexacetonide improves the short term symptom/functional scores of 
viscosupplementation.  
© 2013 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora 
Ltda.   
ARTICLE INFO
Article history:
Received on June 28, 2012
Accepted on August 3, 2012
Keywords:  
Adrenal cortex hormones 
Clinical trial 
Controlled clinical trial 
Double-blind method
Hyaluronic acid 
Injections, intra-articular 
Osteoarthritis, knee 
Pain measurement 
Treatment outcome 
Viscosupplementation
 10.1016/j.rboe.2012.08.005
Este é um artigo Open Access sob a licença de CC BY-NC-ND  
Este é um artigo Open Access sob a licença de CC BY-NC-ND  
 rev bras ortop. 2013;48(4):322-329 323
Palavras-chave: 
Hormônios do córtex adrenal
Ensaio clínico
Ensaio clínico controlado
Método duplo-cego
Ácido hialurônico
Injeções, intra-articular
Osteoartrite do joelho 
Escala de dor 
Tratamento de saída 
Viscossuplementação
r e s u m o
Objetivo: Avaliar se há melhora dos resultados iniciais da viscossuplementação com a 
adição de corticosteroide. Métodos: Foram avaliados 104 pacientes em tratamento para 
osteoartrite do joelho no Instituto de Ortopedia e Traumatologia do Hospital das Clínicas 
da Faculdade de Medicina da Universidade de São Paulo. Os pacientes foram distribuídos 
aleatoriamente para receber uma única injeção intra-articular de 6 mL de Hylan GF-20 
(Grupo 1) ou uma injeção intra-articular de 6 mL de Hylan GF-20, mais 1 mL (20 mg) de 
hexacetonido de triancinolona (Grupo 2). Foram aplicados a escala visual analógica de dor 
(VAS) e os questionários de WOMAC e Lequesne antes da infiltração e após uma, quatro 
e 12 semanas. Resultados: As medidas basais dos dois grupos com 52 pacientes cada não 
apresentaram diferença estatística. Após uma semana, o WOMAC e a VAS mostraram 
resultados significativamente melhores para o Grupo 2 em relação ao Grupo 1 (p < 0,05). 
Com quatro semanas os resultados não apresentaram diferenças estatisticamente 
significativas entre os grupos. Os grupos apresentaram resultados semelhantes na 12ª. 
semana. Conclusão: A adição de hexacetonido de triancinolona melhora os resultados de 
curto prazo da viscossuplementação.
© 2013 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado pela Elsevier Editora 
Ltda.     
Estudo prospectivo e randomizado que avalia a adição de corticoide à 
viscossuplementação: três meses de seguimento
Introduction
Osteoarthritis is the commonest form of joint disease1 and is 
a pathological condition of multifactorial origin that leads to 
destruction of the joint cartilage and inflammatory alterations 
throughout the joint.2 With the progressive increase in life 
expectancy, this pathological condition is further increasing in 
importance, not only with regard to health, but also with regard 
to the costs generated by the disease. In Brazil, a projection 
from the Brazilian Institute for Geography and Statistics 
(IBGE) has indicated that in 2050, the proportion of individuals 
over the age of 65 years, which in 2000 was only 5% of the 
population, will have increased to approximately 18%.3
There are more than 50 methods for treating knee 
osteoarthritis.4 The main treatment options include non-
pharmacological management, pharmacological management,5 
use of intra-articular injections and surgical treatments.6
Intra-articular injections have been used for many years to 
treat painful joint disorders, especially by means of injecting 
crystalline suspensions of long-duration corticosteroids.7 
Viscosupplementation, which is a relatively new intervention, 
consists of injection of exogenous hyaluronic acid into 
diarthrodial joints in order to treat osteoarthritis.8
Hyaluronic acid is a polysaccharide that is produced 
naturally by type B cells of the synovial membrane. Its 
molecules, of high molecular weight, form a high-viscosity 
solution that serves both as a lubricant and as a shock 
absorber.9 Viscosupplementation has short-term efficacy due 
to its pain-relief effect, but it is also considered to be a drug 
that modifies the course of osteoarthritis, with benefits within 
a period lasting for between six months and a few years.10 It 
is believed that the long-term results from hyaluronic acid are 
due to its modulating mechanism of action, especially through 
its interaction with the CD44 receptors of synoviocytes.11
Most placebo-controlled studies demonstrate clinical 
improvement within two to five weeks after the intra-
articular injection of hyaluronic acid.12 In comparing 
viscosupplementation with intra-articular injection of 
corticosteroids, the most recent data suggest that over the 
first four weeks, intra-articular corticosteroids seem to be 
relatively more effective against pain. From the fourth week 
onwards, the two approaches have equal efficacy, but after the 
eighth week, hyaluronic acid has greater efficacy.13 The late 
start, combined with reports of synovitis as a reaction to the 
procedure, may discourage physicians and patients in relation 
to using viscosupplementation.
Objective
To assess whether the initial clinical results from 
viscosupplementation could be improved through addition of 
corticosteroid.
Methods
This  study was conducted in  the Department  of 
Orthopedics and Traumatology, Institute of Orthopedics 
and Traumatology, Hospital das Clínicas, School of Medicine 
of the University of São Paulo (DOT-IOT-HCFMUSP), in 
accordance with the CONSORT guidance (Consolidated 
Standards of Reporting Trials). It was approved by the 
Ethics Committee for Analysis of Research Projects 
(CAPPesq), under no. 0073/10. It was registered on the 
website clinicaltrials.org. This study was fully funded from 
the Research Support Foundation of the State of São Paulo 
(Fapesp) (2010/11450-9). 
In this randomized double-blind prospective clinical 
trial, 104 patients with diagnoses of knee osteoarthritis 
were evaluated. All of the patients were already undergoing 
treatment administered by the osteometabolic disease 
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group of IOT-HCFMUSP. Our usual treatment consisted 
of education through classes, class notes, audiovisual 
material and guidance from orthopedists, nutritionists, 
psychologists, occupational therapists, physical educators 
and social assistants. All the patients, except for those with 
contraindications, were making use of analgesics as required 
(paracetamol and codeine). According to their knee alignment, 
use of shoe insoles would also be indicated. None of the 
patients routinely used non-steroidal anti-inflammatory drugs 
(NSAIDs), and their use was discouraged throughout the study, 
until seven days after the procedure.
Inclusion criteria
- fulfilling the diagnostic criteria for osteoarthritis of the 
American College of Rheumatology;14
- understanding, agreeing with and signing the free and 
informed consent statement;
- absence of any history of previous fracture in the knee to be 
assessed;
- absence of any history of previous surgery in the knee to be 
assessed;
- absence of any history of allergy to any of the substances 
used;
- not having undergone any infiltration in the knee to be 
assessed over the last six months;
- being under treatment with our group for at least six months; 
- not having used NSAIDs over the last seven days.
Exclusion criteria
- undergoing surgery on the knee assessed, during the 
follow-up period;
- need for new infiltration in the knee assessed, during the 
follow-up period;
- severe reaction to the procedure; 
- development of active infection during the study;
- use of NSAIDs at any time. 
One week before the infiltration, the patients were asked 
to fill out the free and informed consent statement, the visual 
analogue pain scale (VAS),15 and the WOMAC16 and Lequesne 
questionnaires.17 The visual scale and the questionnaires were 
also answered one week after the infiltration (week 1)), four 
weeks afterwards (week 4) and 12 weeks afterwards (week 
12). Anteroposterior and lateral radiographs with loading 
on the affected knee were evaluated, and the radiological 
classification was made by three observers using the system 
of Kellgren and Lawrence.18
The patient sample size was estimated by calculating 
an n that would enable statistical power of 80% and a 
significance level of 5%. The patients were randomized into 
two groups of 52 patients each (groups 1 and 2), by means 
of simple randomization generated by a computer program. 
The investigator who performed the randomization did not 
know the patients and did not participate in any intervention. 
The three investigators who performed the infiltrations did 
not have any contact with the patients at any other time. The 
investigators who applied the questionnaires, both before the 
procedure and at the return visits in weeks 1, 4 and 12, did not 
know which group the patients belonged to. The patients were 
not allowed to know which group they belonged to, or to see 
what was being infiltrated. 
The patients in group 1 underwent a viscosupplementation 
procedure in the arthritic knee consisting of infiltration 
of 6 mL of hylan GF-20. The patients in group 2 underwent 
a viscosupplementation procedure in the arthritic knee 
consisting of infiltration of 6 mL of hylan GF-20 and 1 mL (20 
mg) of triamcinolone hexacetonide. 
All the procedures were performed in an outpatient 
environment, using the same technique. The infiltration into 
the knee was done with the patient seated with the knees 
at 90 degrees and lower legs off the bed. The access route 
chosen for the joint injection was an anterolateral route.19 
The procedures were performed by three investigators with 
experience of viscosupplementation. Immediately after the 
procedure, the patients were released without restrictions, with 
the instruction to take paracetamol (500 mg) every 6 hours for 
three days.
To investigate whether the groups differed in relation to 
nominal characteristics, we described the characteristics 
according to the groups using absolute and relative frequencies. 
We investigated whether associations existed by using the chi-
square or Fisher exact test, or the likelihood ratio when the 
sample was insufficient to apply the chi-square test. 
The quantitative characteristics were described according to 
the groups by using summary measurements (mean, standard 
deviation, median, minimum and maximum), and the values 
were compared between the groups by using Student’s t test.
The pain and functionality scales were described according 
to the groups and the times of the evaluations, by using 
summary measurements, and the values were compared 
between the groups and times by using analysis of variance 
with repeated measurements, with two factors that made the 
assumption of a first-order autoregressive correlation matrix 
between the times, followed by Tukey multiple comparisons 
in order to compare the groups and times in pairs. Figure 1 
presents the flow diagram for the study. 
Table 1 describes the nominal characteristics of the 
patients according to the groups, and the results from 
the association tests. In this table, it can be seen that the 
characteristics evaluated did not present any statistically 
significant associations with the groups of patients (p > 0.05), 
i.e. the groups were homogenous in relation to the nominal 
characteristics evaluated. 
Table 2 describes the numerical characteristics of the 
patients according to the groups, and the results from 
the association tests. In this table, it can be seen that the 
characteristics evaluated were on average statistically equal 
in the two groups of patients (p > 0.05).
The numerical characteristics of the preoperative scores 
were on average statistically equal in the two groups of patients, 
with p > 0.05 (Table 3). Table 3 presents the results from the VAS, 
WOMAC, WOMAC pain and Lequesne questionnaires at all the 
times evaluated.
Figure 2 presents the results from the WOMAC questionnaire, 
with a statistically significant reduction in group 1 from week 
4 in relation to the preoperative situation (p < 0.05). Group 2 
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Variable Group 1 Group 2 Total p
 n % n % n %  
Gender 0.819
Male 13 25 12 23.1 25 24
Female 39 75 40 76.9 79 76
Ethnicity 0.823#
Oriental 1 1.9 1 1.9 2 1.9
White 33 63.5 36 69.2 69 66.3
Black 4 7.7 5 9.6 9 8.7
Mixed 14 26.9 10 19.2 24 23.1
Kellgreen & Lawrence 0.969
1 7 13.5 6 11.5 13 12.5
2 14 26.9 16 30.8 30 28.8
3 18 34.6 18 34.6 36 34.6
4 13 25 12 23.1 25 24
Result from chi-square test; # result from Fisher’s exact test..
Table 1 -  Description of the nominal characteristics of the patients according to groups, and results from association tests.
Figure 1 - Flow diagram for the study.
Osteometabolic diseases outpatient 
clinic IOT-FMUSP
250 patients
Fulfilled the inclusion criteria
147 patients
RECRUITMENT
GROUP 1 GROUP 2
RANDOMIZATION
Before infiltration
52 patients
1 patient excluded (severe reaction)
5 patients did not attend return 
visit
2 moved home
3 unknown causes
4 patients did not attend return 
visit 
1 moved home 
3 unknown causes 
             +
1 patient excluded who 
underwent arthroscopy
Before infiltration 
52 patients 
week 1
52 patients
week 1
52 patients
week 4
51 patients
week 4
52 patients 
week 12
46 patients
week 12
47 patients 
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presented a statistically significant mean reduction between 
the preoperative situation and the postoperative weeks 
(p < 0.05), which stabilized. The mean WOMAC value in week 
1 was statistically lower in group 2 than in group 1 (p = 0.038).
Variable Group  Mean  SD                        IC 
MIN     
(95%)      
        MAX
n p 
Age
1 60.75 11.71 57.49 64.01 52
0.062
2 64.65 9.14 62.11 67.2 52
Weight
1 79.63 14.6 75.57 83.7 52
0.136
2 75.77 11.47 72.58 78.96 52
Height
1 1.63 0.09 1.6 1.65 52
0.773
2 1.62 0.08 1.6 1.64 52
BMI
1 30.18 5.24 28.72 31.64 52
0.157
2 28.87 4.08 27.73 30 52
Variable Time Time SD IC (95%) n Mean SD IC (95%) n
    inf sup    inf sup   
WOMAC
Baseline 50.21 16.15 45.71 54.71 52 54.54 17.58 49.65 59.43 52
Week 1 45.83 18.52 40.67 50.98 52 34.38 20.04 28.81 39.96 52
Week 4 39 1.87 33.97 44.03 51 31.75 17.58 26.86 36.64 52
Week 12 34.48 19.25 28.76 40.19 46 36.43 16.5 31.58 41.27 47
Week 24 36.72 19.05 31.06 42.37 46 38.11 16.72 33.2 43.01 47
WOMAC 
Pain
Baseline 9.94 3.64 8.93 10.96 52 10.85 3.68 9.82 11.87 52
Pain 8.87 4.54 7.6 10.13 52 7.04 4.37 5.82 8.25 52
Week 4 7.68 3.95 6.52 8.84 51 6.92 4.28 5.74 8.1 52
Week 12 6.74 3.7 5.64 7.84 46 7.02 3.6 5.97 8.08 47
Week 24 7.33 3.72 6.22 8.43 46 7.47 3.37 6.48 8.46 47
VAS
Baseline 67.27 20.08 61.68 72.86 52 70.21 23.59 63.64 76.78 52
Week 1 55.29 26.52 47.91 62.67 52 38.52 24.65 31.66 45.38 52
Week 4 50.41 24.1 43.63 57.19 51 37.4 25.24 30.38 44.43 52
Week 12 46.22 26.18 38.44 53.99 46 46.7 23.51 39.71 53.68 47
Week 24 49.41 21.94 42.74 56.08 46 50.15 23.46 43.26 57.04 47
Lequesne
Baseline 13.24 3.85 12.17 14.31 52 13.86 4.18 12.69 15.02 52
Week 1 11.86 4.05 10.74 12.99 52 10.93 4.73 9.61 12.25 52
Week 4 10.96 4.13 9.8 12.12 51 9.7 4.12 8.55 10.85 52
Week 12 9.73 4.05 8.52 10.93 46 10.87 3.79 9.74 12 47
Week 24 10.32 4.27 9.02 11.62 46 11.45 3.7 10.36 12.53 47
Table 2 - Description of the numerical characteristics according to groups, and results from comparison tests.
Table 3 - Description of the scales according to groups, and the times evaluated.
From Figure 3, it can be seen that the results from the 
pain scale (VAS) showed a statistically significant reduction 
from the preoperative situation to the other times, in both 
groups (p < 0.05), although in group 2 the mean reduction was 
quantitatively larger. In week 1, the mean value on the pain 
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scale was significantly lower in group 2 than in group 1 (p = 
0.014).
In Figure 4, it can be seen that the mean Lequesne 
value showed a statistically significant reduction from the 
preoperative situation to the times from week 4 onwards 
(p < 0.05) in group 1. In group 2, the mean reduction from 
the preoperative situation to the subsequent weeks already 
presented statistical significance from week 1 onwards 
(p < 0.05). However, in week 24, the mean Lequesne value in 
this group became statistically equal to the preoperative value 
(p = 0.076). There was no statistical difference between the 
groups at any time. 
Figures 2 to 4 suggest that there were earlier reductions on 
the WOMAC and VAS scales in group 2. Figure 3 does not suggest 
that there was a difference on the Lequesne scale between the 
groups, but it seemed that the behavior of the Lequesne scale 
over the course of the evaluations was inconstant. 
There was no statistical difference between the 
groups regarding occurrences of adverse effects from the 
viscosupplementation procedure (Table 4). Among all the 
patients, 17.3% reported having some type of pain or discomfort 
after the infiltration and 4.8% presented joint effusion. Only 
one patient in group 1 presented great pain and large volumes 
of joint effusion, and this patient underwent puncture with 
drainage of the effusion and infiltration of corticosteroids to 
alleviate the symptoms. This patient was excluded from the 
remainder of the study. All the other patients with adverse 
effects presented mild symptoms and were treated with ice, 
analgesics and rest.
Discussion
Improvements were observed in all the patients, but the VAS 
and WOMAC values diminished to lower levels and earlier in 
the group in which corticosteroids were used in association 
with viscosupplementation (group 2). This phenomenon can be 
explained by the faster mechanism of action of corticoids, as 
observed in the literature.13,20 Figures 2 to 4 show two different 
curve patterns for each group over the first four weeks, 
probably due to the effect of the corticosteroid. Group 1 showed 
a gentler curve, thus denoting a mechanism involving greater 
modulation of the action of hyaluronic acid. After reaching the 
fourth week, the results were similar.
Figure 2 - Average profiles and respective standard errors 
for WOMAC score according to groups.
Figure 3 - Average profiles and respective standard errors 
for VAS score according to groups.
Figure 4 - Average profiles and respective standard errors 
for Lequesne score according to groups.
Adverse 
effects
Group 1 Group 2 Total p 
n % n % n %
Pain
- 44 86.5 41 78.8 86 82.7 0.3
+ 8 13.5 11 21.2 18 17.3  
Effusion
- 49 94.2 50 96.2 99 95.2  
3 5.8 2 3.8 5 4.8 > 0,999*
 Table 4 - Description of occurrences of adverse effects 
according to groups, and result from association tests.
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It remains uncertain how the addition of corticosteroids 
affects the modifying effect of hyaluronic acid, despite the 
similar clinical results. To evaluate the progression of the 
disease, objective methods such as measuring the joint space 
(JSW)2,21 or advanced imaging studies like magnetic resonance 
imaging (MRI) have not been used.22 There is also some concern 
regarding the chondrotoxicity of intra-articular corticosteroids, 
but a review of the literature has shown evidence of sufficient 
security regarding this subject.23 A clinical trial with two years 
of follow-up showed that there was no loss of joint space after 
intra-articular injection of triamcinolone hexacetonide at 
three-month intervals.24 
O s t e o a r t h r i t i c  ch o n d ro cy t e s  a re  d e f i c i e n t  i n 
glucocorticoid receptors25 and the weak response to 
circulating corticosteroids may be one of the factors involved 
in the higher levels of cytokines and metalloproteinases in 
osteoarthritic joints. Therefore, in addition to improving 
the initial results from viscosupplementation, it can be 
speculated that addition of triamcinolone hexacetonide 
may even affect the long-term results positively. Further 
studies on this subject are necessary. 
The present study has some limitations. The use of 
analgesics or any non-pharmacological treatment was not 
controlled. However, we believe that viscosupplementation 
is a procedure that should not exclude any other type of 
treatment for osteoarthritis, whether pharmacological or 
not. We maintained the usual treatment and the patients 
were encouraged to continue to use any medication that 
they were using before the viscosupplementation, as 
described earlier. The present study took a pragmatic 
approach that focused not only on efficacy or safety, but 
also attempted to place viscosupplementation within the 
context of the real world, together with the concept of 
efficacy.26
As mentioned earlier, clinical scores such as WOMAC 
and Lequesne are not capable of individualizing one knee 
from the other when the patient has bilateral osteoarthritis. 
Therefore, in the present study, the patients with bilateral 
disease underwent treatment for both knees with the same 
drug, and only the knee that the patient reported to be 
“worse” was taken into consideration. IN the literature, 
there are better results from viscosupplementation in 
patients with less severe osteoarthritis,27 i.e. lower K&L 
levels, but our results did not show a statistical association 
in this regard.
The present study did not have a placebo group that 
received saline injection. There are several studies comparing 
placebo with viscosupplementation and comparing placebo 
injection with corticosteroids. Our aim was to improve the 
results from viscosupplementation, since we believe that 
the issue of its efficacy has already been answered in the 
current literature.12,20 Thus, the present study had a control 
group that also received treatment (viscosupplementation), 
which avoided the ethical problems involved in using a placebo 
group.
Most products containing hyaluronic acid that are available 
on the market have to be administered by means of three to 
five injections. The regimen used for the present study was a 
single dose of 6 mL of hylan GF-20, which is only accepted for 
this product in particular.28 Regarding the type of hyaluronic 
acid used for viscosupplementation, there is no convincing 
evidence to show that one product is superior to another, in 
relation to molecular weight and the concentration or number 
of cross-bonds.12,20 We believe that the results from the present 
study can be extrapolated to viscosupplementation procedures 
in general.
Adverse effects may occur in 4.2% of the patients, such 
as knee effusion, pain, heat and erythema.29 The present 
study found a higher pain rate and a similar rate for effusion. 
Curiously, there was no statistical difference between the 
groups of adverse effects. Another unexpected result was the 
absence, one week after the procedure, of any statistically 
significant difference between the groups, according to 
the WOMAC pain subscale (p = 0.324), in contrast with the 
comparison made using the total WOMAC scale at the same 
time point. This may provide proof of the good analgesic effect 
of viscosupplementation. 
Conclusion
Addition of 1 ml of triamcinolone hexacetonide significantly 
improved the pain and function results from viscosupplemen-
tation over the short term. 
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